RETA — Reata Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge Cap
- $6.52bn
- $6.27bn
- $2.22m
Brief: Reata Pharmaceuticals Says Manmeet Soni Promoted To President Of Co
Brief: Reata Pharmaceuticals Initiates Rolling Submission Of New Drug Application With U.S. FDA For Omaveloxolone
U.S. STOCKS ON THE MOVE-American Airlines, GameStop, EVgo, Kinross Gold, SPI Energy
Reata Pharma eyes over 3-year low on U.S. FDA decision
Brief: Reata Pharmaceuticals Announces Outcome Of FDA Advisory Committee Meeting Of Bardoxolone
NASDAQ RESUMED AT 10:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 10:28 AM
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 10:06 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 09:43 AM
NASDAQ RESUMED AT 09:45 AM
Brief: Reata Pharmaceuticals Stock Trading Halted Today FDA Advisory Committee To Discuss Bardoxolone For Treatment Of Patients With Chronic Kidney Disease Caused By Alport Syndrome
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Reata Pharma slumps as FDA staff raises concerns over kidney drug safety, efficacy
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:35 AM
Brief: Reata Pharmaceuticals Gets Fast Track Designation From The FDA For Omaveloxolone For The Treatment Of Friedreich'S Ataxia
Reata Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Reata Pharmaceuticals Inc Announces Q3 2021 Financial Results, Provides An Update On Clinical Development Programs
Brief: Reata Pharmaceuticals Announces Presentations At The American Society Of Nephrology Kidney Week 2021